Equity Profile

ILMN

Illumina, Inc.

Health CareLife Sciences Tools & Services$24.6B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Illumina, Inc. is a leading company in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and performance, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and drive sales, crucial for investor confidence.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ILMN Q2-2026 Earnings Preview

Context

Company Snapshot

Illumina, Inc. is a leading company in the health care sector, specializing in life sciences tools and services. It plays a crucial role in genetic sequencing and analysis, which is increasingly important in personalized medicine and biotechnology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+111.82%

Avg Stock Reaction

+1.42%

Last Quarter Recap

In the last quarter, Illumina reported an EPS of $1.15, beating expectations by nearly 10%. The stock reacted positively, gaining over 5% the following day.

Management Promises & Guidance

Continued focus on innovation in genetic sequencing technology.
Commitment to expanding market presence in personalized medicine.
Plans to enhance customer engagement and support services.

Expectations

Wall Street Expectations

Overall, expectations are mixed as investors await clarity on revenue growth and profitability metrics. The stock has historically reacted positively to earnings beats.

Bull Case

If Illumina continues its trend of beating EPS estimates, it could signal strong operational performance and market demand, leading to significant stock appreciation.

Bear Case

Conversely, if the company fails to meet revenue expectations or shows signs of slowing growth, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported revenue growth rate for the quarter?

Revenue growth is critical for assessing the company's market position and future prospects, especially in a competitive landscape.

How will gross margins be affected by recent cost pressures?

Understanding gross margins will provide insight into the company's operational efficiency and pricing strategy, which are vital for profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Illumina's ability to leverage new technologies in genetic sequencing, which could drive higher-than-expected revenue growth.

Supporting Evidence

Illumina has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing a larger move than historical averages, suggesting potential for significant surprises.

Recent industry trends indicate increasing demand for genetic testing and personalized medicine, which Illumina is well-positioned to capitalize on.

Key Risk

If revenue growth comes in below 10%, it could challenge the bullish narrative surrounding the company's market position.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around Illumina's ability to sustain growth in a rapidly evolving biotechnology sector.

Bull Confirmed If

A revenue growth rate exceeding 15% would confirm strong market demand and operational success.

Bear Confirmed If

Revenue growth below 5% would raise concerns about market competitiveness and demand.

Pre-Earnings Positioning

Options Market

Implied Move

±19.2%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±19.2% while ILMN has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

41.8%

Calls (160K)P/C Ratio: 0.12Puts (26K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Illumina beats expectations, history suggests a potential stock increase of around 1.42%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may see muted reactions as investors reassess growth prospects.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around 3.10% following disappointing results.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their expected impact on revenue.
2Any commentary on competitive pressures in the genetic sequencing market.
3Insights into customer demand trends for genetic testing services.
4Management's outlook on future revenue growth and market expansion.
5Details on cost management strategies and their effect on gross margins.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

KRCAMC

Kilroy Realty Corporation

PreviewView

Jul27

PIIAMC

Company Snapshot

Illumina, Inc. is a leading company in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and performance, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and drive sales, crucial for investor confidence.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ILMN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+111.82%

Avg Stock Reaction

+1.42%

Last Quarter Recap

In the last quarter, Illumina reported an EPS of $1.15, beating expectations by nearly 10%. The stock reacted positively, gaining over 5% the following day.

Management Promises & Guidance

Continued focus on innovation in genetic sequencing technology.
Commitment to expanding market presence in personalized medicine.
Plans to enhance customer engagement and support services.

Expectations

Wall Street Expectations

Overall, expectations are mixed as investors await clarity on revenue growth and profitability metrics. The stock has historically reacted positively to earnings beats.

Bull Case

If Illumina continues its trend of beating EPS estimates, it could signal strong operational performance and market demand, leading to significant stock appreciation.

Bear Case

Conversely, if the company fails to meet revenue expectations or shows signs of slowing growth, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported revenue growth rate for the quarter?

Revenue growth is critical for assessing the company's market position and future prospects, especially in a competitive landscape.

How will gross margins be affected by recent cost pressures?

Understanding gross margins will provide insight into the company's operational efficiency and pricing strategy, which are vital for profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Illumina's ability to leverage new technologies in genetic sequencing, which could drive higher-than-expected revenue growth.

Supporting Evidence

Illumina has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing a larger move than historical averages, suggesting potential for significant surprises.

Recent industry trends indicate increasing demand for genetic testing and personalized medicine, which Illumina is well-positioned to capitalize on.

Key Risk

If revenue growth comes in below 10%, it could challenge the bullish narrative surrounding the company's market position.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around Illumina's ability to sustain growth in a rapidly evolving biotechnology sector.

Bull Confirmed If

A revenue growth rate exceeding 15% would confirm strong market demand and operational success.

Bear Confirmed If

Revenue growth below 5% would raise concerns about market competitiveness and demand.

Pre-Earnings Positioning

Options Market

Implied Move

±19.2%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±19.2% while ILMN has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

41.8%

Calls (160K)P/C Ratio: 0.12Puts (26K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Illumina beats expectations, history suggests a potential stock increase of around 1.42%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may see muted reactions as investors reassess growth prospects.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around 3.10% following disappointing results.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their expected impact on revenue.
2Any commentary on competitive pressures in the genetic sequencing market.
3Insights into customer demand trends for genetic testing services.
4Management's outlook on future revenue growth and market expansion.
5Details on cost management strategies and their effect on gross margins.